Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP082
MIFTS: 51

Hypopharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hypopharynx Cancer

About this section

MalaCards integrated aliases for Hypopharynx Cancer:

Name: Hypopharynx Cancer 11 14 16
Hypopharyngeal Cancer 11 19 53 71 75
Malignant Neoplasm of Hypopharynx 11 31
Hypopharyngeal Neoplasms 43 71
Hypopharyngeal Carcinoma 16 71
Malignant Tumour of Hypopharynx 11
Malignant Hypopharyngeal Tumor 11
Malignant Tumor of Hypopharynx 11

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:8533
ICD9CM 34 148 148.3
MeSH 43 D007012
NCIt 49 C7190
SNOMED-CT 68 93831006 93968005
ICD10 31 C13 C13.2 C13.9
UMLS 71 C0020627 C0153398 C0496770 more
Sources

Summaries for Hypopharynx Cancer

About this section

Disease Ontology: 11 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary: Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to laryngeal benign neoplasm and larynx cancer. An important gene associated with Hypopharynx Cancer is MIR489 (MicroRNA 489), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Nicotinamide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include hypopharynx, lymph node and tongue, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Wikipedia: 75 Hypopharyngeal cancer is a disease in which malignant cells grow in the hypopharynx (also known as the... more...
Sources

Related Diseases for Hypopharynx Cancer

About this section

Diseases related to Hypopharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 413)
# Related Disease Score Top Affiliating Genes
1 laryngeal benign neoplasm 30.4 TP53 EGFR CDKN2A CAGE1
2 larynx cancer 30.3 TP53 NME1 MIR143 EGFR BCL2
3 lip and oral cavity cancer 30.3 TP53 EGFR CDKN2A CDH1
4 oropharynx cancer 30.1 TP53 EGFR CDKN2A CDH1 CD274 BCL2
5 spinal cord disease 30.0 TP53 EGFR CDKN2A AKT1
6 squamous cell carcinoma 29.9 TP53 STAT3 NME1 EGFR CDKN2A CDH1
7 carcinosarcoma 29.9 TP53 EGFR CDKN2A CDH1 CD274
8 adenoma 29.7 TP53 CDKN2A CDH1 BCL2 AKT1
9 keratoacanthoma 29.6 TP53 STAT3 EGFR CDH1 BCL2
10 laryngeal squamous cell carcinoma 29.6 TP53 STAT3 NME1 EGFR CDKN2A CDH1
11 papilloma 29.5 TP53 EGFR CDKN2A CDH1 BCL2 AKT1
12 squamous cell carcinoma, head and neck 29.5 TP53 STAT3 MIR143 MET EGFR CDKN2A
13 b-cell lymphoma 29.4 TP53 STAT3 CDKN2A CD274 BCL2 AKT1
14 amyotrophic lateral sclerosis 1 29.2 TP53 STAT3 NGFR MIR143 BCL2 AKT1
15 nasopharyngeal carcinoma 29.2 TP53 STAT3 NME1 MIR143 EGFR CDKN2A
16 esophageal cancer 29.1 TP53 STAT3 NME1 MIR143 MET EGFR
17 lung cancer susceptibility 3 29.0 TP53 STAT3 MIR143 MET EGFR CDKN2A
18 diabetes mellitus 28.9 TP53 STAT3 MIR143 EGFR CDKN2A CD274
19 head and neck cancer 28.8 TP53 STAT3 PRB4 MIR143 EGFR CDKN2A
20 gastric cancer 28.6 TP53 STAT3 SNHG7 NME1 MIR143 MET
21 tonsillar pillar cancer 10.4 EGFR CDKN2A
22 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.3 TP53 CDKN2A
23 endometrial squamous cell carcinoma 10.3 TP53 CDKN2A
24 penis basal cell carcinoma 10.3 CDKN2A CDH1
25 papillary squamous carcinoma 10.3 EGFR CDKN2A
26 frontal lobe neoplasm 10.3 TP53 EGFR
27 tetraploidy 10.3 TP53 NGFR
28 idh-wildtype glioblastoma 10.3 TP53 EGFR CDKN2A
29 adult malignant schwannoma 10.3 TP53 EGFR CDKN2A
30 mixed glioma 10.3 TP53 EGFR CDKN2A
31 cervical adenocarcinoma 10.3 TP53 NME1 CDKN2A
32 urethra transitional cell carcinoma 10.3 TP53 EGFR
33 adenocarcinoma in situ 10.3 TP53 EGFR CDKN2A
34 plexiform neurofibroma 10.3 TP53 EGFR CDKN2A
35 bizarre leiomyoma 10.3 TP53 CDKN2A
36 diffuse astrocytoma 10.3 TP53 EGFR CDKN2A
37 mucinous adenocarcinoma 10.3 TP53 EGFR CDKN2A
38 lung sarcomatoid carcinoma 10.3 MET EGFR CD274
39 early invasive cervical adenocarcinoma 10.3 CDKN2A BCL2
40 penile benign neoplasm 10.3 TP53 CDKN2A CD274
41 lobular neoplasia 10.3 TP53 EGFR CDH1
42 pleomorphic carcinoma 10.3 TP53 EGFR CD274
43 sinus cancer 10.3
44 peritoneal mesothelioma 10.2 TP53 CDKN2A CD274
45 anaplastic oligodendroglioma 10.2 TP53 EGFR CDKN2A
46 inflammatory myofibroblastic tumor 10.2 TP53 MET EGFR
47 good syndrome 10.2 TP53 EGFR CD274
48 thoracic benign neoplasm 10.2 TP53 EGFR CDH1
49 breast benign neoplasm 10.2 TP53 EGFR CDH1
50 ampulla of vater cancer 10.2 TP53 EGFR CDKN2A

Comorbidity relations with Hypopharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer
Sources

Symptoms & Phenotypes for Hypopharynx Cancer

About this section

GenomeRNAi Phenotypes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

25 (show top 50) (show all 59)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.1 MET
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.1 CD274
3 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.1 BCL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.1 MET
5 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.1 MET NME1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.1 NME1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.1 EGFR
8 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.1 STAT3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-134 10.1 BCL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.1 BCL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.1 BCL2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.1 ALDH2 CD274 STAT3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.1 ALDH2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.1 MET
15 Increased shRNA abundance (Z-score > 2) GR00366-A-187 10.1 CD274
16 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.1 MET
17 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.1 BCL2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.1 BCL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.1 MET
20 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.1 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.1 BCL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.1 STAT3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.1 AKT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.1 EGFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-216 10.1 NME1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.1 CD274
27 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.1 CD274
28 Increased shRNA abundance (Z-score > 2) GR00366-A-33 10.1 ALDH2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.1 ALDH2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.1 BCL2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-38 10.1 MET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.1 MET
33 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.1 ALDH2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.1 EGFR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.1 NME1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.1 NME1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-59 10.1 BCL2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.1 AKT1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.1 MET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.1 BCL2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.1 AKT1 BCL2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-75 10.1 NME1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.1 BCL2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.1 MET
45 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.1 ALDH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.1 AKT1 ALDH2 CD274 EGFR MET NME1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.1 ALDH2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.1 BCL2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.1 EGFR
50 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.1 BCL2

MGI Mouse Phenotypes related to Hypopharynx Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.1 AKT1 ALDH2 BCL2 CDH1 CDKN2A EGFR
2 muscle MP:0005369 10.02 AKT1 ALDH2 BCL2 CDKN2A EGFR MET
3 liver/biliary system MP:0005370 9.97 AKT1 ALDH2 CDKN2A EGFR MET NGFR
4 endocrine/exocrine gland MP:0005379 9.96 AKT1 ALDH2 BCL2 CDH1 CDKN2A EGFR
5 digestive/alimentary MP:0005381 9.76 BCL2 CDH1 CDKN2A EGFR MET NGFR
6 cardiovascular system MP:0005385 9.7 AKT1 ALDH2 BCL2 CDH1 CDKN2A EGFR
7 integument MP:0010771 9.36 AKT1 ALDH2 BCL2 CD274 CDH1 CDKN2A
Sources

Drugs & Therapeutics for Hypopharynx Cancer

About this section

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 5702198 441203
3
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
6
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
7
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
8
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
9
Cetuximab Approved Phase 2, Phase 3 205923-56-4
10
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
12
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
13 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
14 Vitamins Phase 3
15 Folate Phase 3
16 Vitamin B9 Phase 3
17 Vitamin B3 Phase 3
18 Trace Elements Phase 3
19 Nicotinic Acids Phase 3
20 Vasodilator Agents Phase 3
21 Vitamin B Complex Phase 3
22 Hypolipidemic Agents Phase 3
23 Lipid Regulating Agents Phase 3
24 Micronutrients Phase 3
25 Antimitotic Agents Phase 3
26 Tubulin Modulators Phase 3
27 Albumin-Bound Paclitaxel Phase 3
28 Endothelial Growth Factors Phase 2, Phase 3
29 Mitogens Phase 2, Phase 3
30 Immunosuppressive Agents Phase 3
31 Angiogenesis Inhibitors Phase 2, Phase 3
32 Antineoplastic Agents, Immunological Phase 2, Phase 3
33 Immunologic Factors Phase 2, Phase 3
34 Immunoglobulins, Intravenous Phase 2, Phase 3
35 Immunoglobulin G Phase 2, Phase 3
36 Antibodies, Monoclonal Phase 2, Phase 3
37 Pharmaceutical Solutions Phase 3
38 Raspberry Approved Phase 1, Phase 2
39
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
40
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
41
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
42
Nivolumab Approved Phase 2 946414-94-4
43
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
44
Doxepin Approved, Investigational Phase 2 1668-19-5 667468 667477
45
Histamine Approved, Investigational Phase 2 51-45-6 774
46
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
47
Promethazine Approved, Investigational Phase 2 60-87-7 4927
48
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
49
Arginine Approved, Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
50
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
2 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
3 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
4 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
5 A Randomized Phase III Comparing Sequential Therapy With Induction Chemotherapy/Chemoradiation To Cisplatinum-Based Chemoradiotherapy in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT04502641 Phase 3 Docetaxel;5-fluorouracil;Cisplatin;Platinum
6 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Recruiting NCT05063552 Phase 2, Phase 3 Carboplatin;Cisplatin;Docetaxel
7 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Active, not recruiting NCT03258554 Phase 2, Phase 3
8 Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
9 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
10 Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness Completed NCT00243113 Phase 2 docetaxel
11 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
12 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
13 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
14 A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab Completed NCT01435252 Phase 2 Cetuximab
15 A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy Completed NCT03096808 Phase 2
16 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
17 Induction Chemotherapy Combined With Camrelizumab Followed by Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Cancer Recruiting NCT04539600 Phase 2 Camrelizumab
18 New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT03558035 Phase 2 Induction CT+ CRT group
19 Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma Recruiting NCT05420597 Phase 2 Toripalimab
20 Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma Recruiting NCT04995120 Phase 2 chemotherapy TP regimen combined with Toripalimab
21 Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) Recruiting NCT02757222 Phase 1, Phase 2
22 RESILIENCE: Effect of Comprehensive Celecoxib Through Treatment for Advanced-Stage Head and Neck Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial Recruiting NCT04162873 Phase 2 Celecoxib
23 A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Recruiting NCT05172258 Phase 2 Ipatasertib
24 A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting NCT04862650 Phase 2 Carboplatin;Paclitaxel
25 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin
26 Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study Recruiting NCT05136196 Phase 2 Cabozantinib S-malate
27 A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT04156698 Phase 2 Docetaxel;Cisplatin;Capecitabine;Camrelizumab
28 Hypofractionated Proton Therapy for the Treatment of Head and Neck Cancer, The HEADLIGHT Study" Recruiting NCT05075980 Phase 2 Cisplatin
29 Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer Active, not recruiting NCT03894891 Phase 2 Nivolumab;Cisplatin;Docetaxel
30 An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Active, not recruiting NCT03082534 Phase 2 Pembrolizumab, Cetuximab
31 A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin Active, not recruiting NCT04541355 Phase 2 Cisplatin;Sodium Thiosulfate
32 Toripalimab Plus TPF Inductive Chemotherapy and Definitive Radiotherapy for Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Efficacy and Safety: a Phase II Prospective Cohort Study Not yet recruiting NCT04624308 Phase 2 Toripalimab
33 A Single-arm Study Evaluating Efficacy and Safety of Toripalimab Combined With Docetaxel and Cisplatin as Induced Chemotherapy in the Treatment of Localized Hypopharyngeal Squamous Cell Carcinoma Not yet recruiting NCT04296747 Phase 2 induction chemotherapy
34 A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy Terminated NCT02062632 Phase 2 Doxepin Hydrochloride
35 A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT02113878 Phase 1 BKM120;Cisplatin
36 Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer Recruiting NCT05172245 Phase 1 Cisplatin;Ipatasertib
37 Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma Recruiting NCT04576091 Phase 1 Elimusertib
38 Proton Image-Guided Radiation Assignment for Therapeutic Escalation Via Selection of Locally Advanced Head and Neck Cancer Patients [PIRATES] Recruiting NCT04870840 Phase 1
39 Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02586207 Phase 1 pembrolizumab (MK-3475);Cisplatin
40 A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN) Not yet recruiting NCT04892875 Phase 1 Zimberelimab;Etrumadenant;Cisplatin
41 Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Suspended NCT04533750 Phase 1 Peposertib
42 Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck Terminated NCT00080028 Phase 1 Motexafin Gadolinium Injection
43 The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00174096
44 The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Unknown status NCT00173381
45 The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00302562
46 A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients Unknown status NCT03039465
47 Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma Unknown status NCT01171235
48 Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer Completed NCT03132727
49 Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery Completed NCT00473564
50 Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial Completed NCT03934294 Metoclopramide 10mg

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Sources

Genetic Tests for Hypopharynx Cancer

About this section
Sources

Anatomical Context for Hypopharynx Cancer

About this section

Organs/tissues related to Hypopharynx Cancer:

FMA: Hypopharynx
MalaCards : Lymph Node, Tongue, Endothelial, Thyroid, Skin, Bone Marrow, T Cells
Sources

Publications for Hypopharynx Cancer

About this section

Articles related to Hypopharynx Cancer:

(show top 50) (show all 2015)
# Title Authors PMID Year
1
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). 46
20700123 2010
2
[Expression of CD44 and nm23-H1 protein in the primary and metastatic lymph node lesions in supraglottic and hypopharyngeal cancer]. 53 62
16848180 2006
3
Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. 53 62
16308260 2006
4
Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. 53 62
9555115 1998
5
Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors. 62
36317648 2023
6
Metastatic Papillary Thyroid Cancer Mimicking Hypopharyngeal Carcinoma. 62
36469069 2023
7
Tumour microbiota structure predicts hypopharyngeal carcinoma recurrence and metastasis. 62
36407282 2023
8
Single-cell discovery of the scene and potential immunotherapeutic target in hypopharyngeal tumor environment. 62
36460803 2022
9
Oncological outcomes from surgical vs. non-surgical treatments for advanced hypopharyngeal squamous cell carcinoma: a surveillance, epidemiology, and end results-based study. 62
35882729 2022
10
Pretherapy platelet-to-lymphocyte ratio as a prognostic parameter for locally advanced hypopharyngeal cancer patients treated with radiotherapy combined with chemotherapy. 62
35849189 2022
11
Severe obstructive sleep apnea after concurrent chemoradiotherapy for laryngeal and hypopharyngeal cancer managed by CPAP. 62
34108099 2022
12
Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma. 62
36261585 2022
13
Tracheostomy dependence following "organ preservation" (chemo)radiation protocol for laryngeal and hypopharyngeal cancers. 62
36121012 2022
14
Patterns of failure for hypopharynx cancer patients treated with limited high-dose radiotherapy treatment volumes. 62
36456541 2022
15
Detailed analysis of failure patterns using deformable image registration in hypopharyngeal cancer patients treated with sequential boost intensity-modulated radiotherapy. 62
36373823 2022
16
Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial. 62
36447152 2022
17
[Metabolic Tumor Imaging in Head and Neck Oncology]. 62
36415988 2022
18
Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival. 62
36173618 2022
19
Synchronous Second Primary Cancers of Hypopharyngeal Carcinoma in the Image-Enhanced Endoscopy Era. 62
36321782 2022
20
ASO Visual Abstract: Distinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment. 62
36418794 2022
21
Delayed oral feeding reduces pharyngocutaneous fistula formation after open surgical treatment of primary hypopharyngeal cancer: A case-control study. 62
36345057 2022
22
Carotid arterial blowout after organ preserving chemoradiation therapy in hypopharyngeal cancer. 62
36397450 2022
23
Survival outcomes in hypopharyngeal cancer in the West of Scotland Cancer Network. 62
36344424 2022
24
Neutrophil-to-lymphocyte and hypopharyngeal cancer prognosis: System review and meta-analysis. 62
36367335 2022
25
Distinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment. 62
36336733 2022
26
CT-based radiomics signature analysis for evaluation of response to induction chemotherapy and progression-free survival in locally advanced hypopharyngeal carcinoma. 62
35608663 2022
27
Outcomes of surgical versus non-surgical treatment of resectable T4a laryngeal and hypopharyngeal carcinoma. 62
35300741 2022
28
Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer. 62
34423708 2022
29
Role of immune-inflamed phenotype in the prognosis of hypopharyngeal carcinoma following primary surgery. 62
36222335 2022
30
RELA is required for CD271 expression and stem-like characteristics in hypopharyngeal cancer. 62
36273237 2022
31
Association between γ-Glutamyltransferase and Head and Neck Cancer in Korean Population: A National Population-Based Study. 62
35944063 2022
32
Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer. 62
36303119 2022
33
Downhill varices in the hypopharynx due to huge thyroid tumor: a case report. 62
36273906 2022
34
CCS-Net: Cascade Detection Network with the Convolution Kernel Switch Block and Statistics Optimal Anchors Block in Hypopharyngeal Cancer MRI. 62
36282819 2022
35
Pharyngocutaneous Fistula Following Primary and Salvage Laryngectomy: Aetiology and Predictive Factors. 62
36452720 2022
36
A new nomogram to predict oncological outcome in laryngeal and hypopharyngeal carcinoma patients after laryngopharyngectomy. 62
36183023 2022
37
A rare case of Pseudomonas aeruginosa enteritis induced by pembrolizumab. 62
36114073 2022
38
Impact of prior cancer history on survival of patients with hypopharyngeal cancer. 62
36057955 2022
39
Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation. 62
36090478 2022
40
Evaluation of chronological changes in videofluorographic findings after transoral videolaryngoscopic surgery to reveal mechanism of dysphagia. 62
36075789 2022
41
[Application of transverse cervical artery flap in laryngeal function preservation surgery of hypopharyngeal carcinoma]. 62
36111478 2022
42
Survival and swallowing function outcome impact factors analysis of surgery-oriented comprehensive treatment for hypopharyngeal cancer in a series of 122 patients. 62
34792398 2022
43
Reducing complications in reconstruction of the cervical esophagus with anterolateral thigh flap: The five points protocol. 62
35614011 2022
44
The management of metastatic neck nodes following induction chemotherapy in N2/3 classification hypopharyngeal carcinoma. 62
35915865 2022
45
Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma. 62
35915867 2022
46
Oncological and functional outcomes of transoral laser surgery for hypopharyngeal carcinoma. 62
36056169 2022
47
Hypopharyngeal carcinoma in Finland from 2005 to 2014: outcome remains poor after major changes in treatment. 62
36094562 2022
48
Adipofascial anterolateral thigh free flap in hypopharyngeal and oropharyngeal reconstruction. 62
35043476 2022
49
[The effect of cervical lymph node metastasis density on prognosis of hypopharyngeal carcinoma]. 62
36058662 2022
50
Deep learning approach of diffusion-weighted imaging as an outcome predictor in laryngeal and hypopharyngeal cancer patients with radiotherapy-related curative treatment: a preliminary study. 62
35201406 2022
Sources

Variations for Hypopharynx Cancer

About this section
Sources

Expression for Hypopharynx Cancer

About this section
Search GEO for disease gene expression data for Hypopharynx Cancer.
Sources

Pathways for Hypopharynx Cancer

About this section

Pathways related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.82 TP53 STAT3 NGFR MET EGFR CDKN2A
2
Signal Transduction 66
13.79 AKT1 BCL2 CD274 CDH1 EGFR MET
3
GPCR Pathway 64
Show member pathways
 13.71 TP53 STAT3 NGFR MET EGFR CDKN2A
4
TGF-Beta Pathway 64
Show member pathways
 13.54 AKT1 BCL2 CDH1 EGFR MET NGFR
5
Akt Signaling 64
Show member pathways
 13.42 TP53 STAT3 NGFR MET EGFR BCL2
6
PI3K-Akt signaling pathway 74
Show member pathways
 12.94 TP53 NGFR MET EGFR BCL2 AKT1
7
TNFR1 Pathway 64
Show member pathways
 12.92 TP53 NGFR EGFR CDKN2A BCL2 AKT1
8
Signaling by Receptor Tyrosine Kinases 66
12.84 STAT3 MET EGFR CD274 AKT1
9
fMLP Pathway 64
Show member pathways
 12.76 TP53 STAT3 MET CDH1 AKT1
10
Programmed Cell Death 66
Show member pathways
 12.62 TP53 STAT3 CDKN2A CDH1 BCL2 AKT1
11
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.6 TP53 STAT3 NGFR MET EGFR AKT1
12
Immune response IL-23 signaling pathway 22
Show member pathways
 12.57 TP53 STAT3 EGFR BCL2 AKT1
13
Breast cancer pathway 74
Show member pathways
 12.46 TP53 STAT3 EGFR AKT1
14
Development EGFR signaling pathway 22
Show member pathways
 12.46 TP53 STAT3 EGFR CDH1 AKT1
15
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.42 AKT1 BCL2 EGFR STAT3
16
Death Receptor Signaling 67
Show member pathways
 12.36 TP53 NGFR BCL2 AKT1
17
Endometrial cancer 74
Show member pathways
 12.32 TP53 STAT3 EGFR CDKN2A CDH1 BCL2
18
Focal adhesion 74
12.29 MET EGFR BCL2 AKT1
19
NF-kappaB Pathway 70
Show member pathways
 12.29 TP53 NGFR MET EGFR BCL2 AKT1
20
Ras signaling 74
12.25 AKT1 EGFR MET NGFR
21
MAPK Signaling: Mitogens 65
Show member pathways
 12.18 TP53 MET EGFR BCL2 AKT1
22
Intrinsic Pathway for Apoptosis 66
Show member pathways
 12.18 TP53 STAT3 CDKN2A BCL2 AKT1
23
Colorectal Cancer Metastasis 64
12.13 TP53 STAT3 EGFR CDH1 AKT1
24
mTOR Signaling 65
12.07 TP53 MET EGFR AKT1
25
Integrated breast cancer pathway 74
12.05 TP53 EGFR CDH1 BCL2 AKT1
26
Direct p53 effectors 61
12.03 TP53 MET EGFR BCL2
27
MAPK Pathway 70
Show member pathways
 11.99 AKT1 EGFR STAT3 TP53
28
Hepatocyte growth factor receptor signaling 74
Show member pathways
 11.93 TP53 STAT3 NGFR MET CDH1 BCL2
29
Interleukin-4 and Interleukin-13 signaling 66
11.92 TP53 STAT3 BCL2 AKT1
30
Small cell lung cancer 74
11.89 TP53 BCL2 AKT1
31
Malignant pleural mesothelioma 74
11.89 TP53 NGFR MET EGFR CDKN2A CDH1
32
Hippo-Merlin signaling dysregulation 74
Show member pathways
 11.87 NGFR MET EGFR
33
Clear cell renal cell carcinoma pathways 74
11.83 AKT1 EGFR STAT3
34
Regulation of TP53 Expression and Degradation 66
Show member pathways
 11.77 TP53 CDKN2A AKT1
35
Burn wound healing 74
11.77 TP53 BCL2 AKT1
36
Acute viral myocarditis 74
11.76 STAT3 BCL2 AKT1
37
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) 61
11.73 MET CDH1 AKT1
38
Neural crest cell migration in cancer 74
Show member pathways
 11.7 AKT1 NGFR STAT3
39
Head and neck squamous cell carcinoma 74
11.7 AKT1 CDKN2A EGFR TP53
40
Gastrin signaling pathway 74
11.7 STAT3 EGFR CDKN2A CDH1 AKT1
41
p75(NTR)-mediated signaling 61
Show member pathways
 11.69 AKT1 NGFR TP53
42
Hepatitis C and hepatocellular carcinoma 74
11.6 TP53 STAT3 AKT1
43
NRP1-triggered signaling pathways in pancreatic cancer 74
11.58 MET EGFR AKT1
44
p53 pathway 61
11.55 TP53 CDKN2A AKT1
45
FGF signaling pathway 61
11.53 STAT3 MET CDH1 AKT1
46
Signaling events mediated by PTP1B 61
11.51 STAT3 EGFR AKT1
47
Signaling events mediated by TCPTP 61
Show member pathways
 11.5 STAT3 MET EGFR
48
Interleukin-11 signaling pathway 74
11.48 STAT3 BCL2 AKT1
49
Stabilization and expansion of the E-cadherin adherens junction 61
11.46 MET EGFR CDH1
50
Inhibition of Signaling by Overexpressed EGFR 66
Show member pathways
 11.43 AKT1 BCL2 EGFR
Sources

GO Terms for Hypopharynx Cancer

About this section

Biological processes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.97 STAT3 NME1 MET EGFR CDKN2A AKT1
2 cell population proliferation GO:0008283 9.8 AKT1 BCL2 EGFR STAT3 TP53
3 B cell lineage commitment GO:0002326 9.71 TP53 BCL2
4 response to UV-A GO:0070141 9.62 EGFR AKT1
5 T cell lineage commitment GO:0002360 9.61 TP53 BCL2
6 negative regulation of autophagy GO:0010507 9.56 STAT3 MET BCL2 AKT1
7 positive regulation of miRNA maturation GO:1903800 9.46 TP53 EGFR
8 apoptotic mitochondrial changes GO:0008637 9.46 CDKN2A BCL2 AKT1
9 positive regulation of miRNA transcription GO:1902895 9.17 TP53 STAT3 NGFR EGFR

Molecular functions related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.28 TP53 STAT3 MET EGFR BCL2
2 nitric-oxide synthase regulator activity GO:0030235 9.26 EGFR AKT1
Sources

Sources for Hypopharynx Cancer

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....